LT3768729T - Stanozololio ir hialurono rūgšties konjugatai - Google Patents

Stanozololio ir hialurono rūgšties konjugatai

Info

Publication number
LT3768729T
LT3768729T LTEPPCT/IB2019/052034T LTIB2019052034T LT3768729T LT 3768729 T LT3768729 T LT 3768729T LT IB2019052034 T LTIB2019052034 T LT IB2019052034T LT 3768729 T LT3768729 T LT 3768729T
Authority
LT
Lithuania
Prior art keywords
stanozolol
conjugates
hyaluronic acid
hyaluronic
acid
Prior art date
Application number
LTEPPCT/IB2019/052034T
Other languages
English (en)
Inventor
Paolo Giulio PREDIERI
Original Assignee
Acme Drugs S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acme Drugs S.R.L. filed Critical Acme Drugs S.R.L.
Publication of LT3768729T publication Critical patent/LT3768729T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/20Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/43Hormones, e.g. dexamethasone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cosmetics (AREA)
  • Materials For Medical Uses (AREA)
LTEPPCT/IB2019/052034T 2018-03-21 2019-03-13 Stanozololio ir hialurono rūgšties konjugatai LT3768729T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102018000003841A IT201800003841A1 (it) 2018-03-21 2018-03-21 Coniugati di stanozololo e acido ialuronico
PCT/IB2019/052034 WO2019180548A1 (en) 2018-03-21 2019-03-13 Conjugates of stanozolol and hyaluronic acid

Publications (1)

Publication Number Publication Date
LT3768729T true LT3768729T (lt) 2022-05-25

Family

ID=62597894

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/IB2019/052034T LT3768729T (lt) 2018-03-21 2019-03-13 Stanozololio ir hialurono rūgšties konjugatai

Country Status (21)

Country Link
US (1) US11013813B2 (lt)
EP (1) EP3768729B1 (lt)
JP (1) JP7301392B2 (lt)
KR (1) KR102709660B1 (lt)
CN (1) CN111868097B (lt)
AU (1) AU2019240175B2 (lt)
CA (1) CA3094277A1 (lt)
CY (1) CY1124939T1 (lt)
DK (1) DK3768729T3 (lt)
ES (1) ES2908887T3 (lt)
HR (1) HRP20220166T1 (lt)
HU (1) HUE058230T2 (lt)
IL (1) IL277319B2 (lt)
IT (1) IT201800003841A1 (lt)
LT (1) LT3768729T (lt)
MX (1) MX2020009680A (lt)
PL (1) PL3768729T3 (lt)
PT (1) PT3768729T (lt)
RS (1) RS63033B1 (lt)
SI (1) SI3768729T1 (lt)
WO (1) WO2019180548A1 (lt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107289A (en) * 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
CA2559188C (en) * 2004-03-05 2013-01-08 Denki Kagaku Kogyo Kabushiki Kaisha Hyaluronic acid-methotrexate conjugate
ITMI20061609A1 (it) * 2006-08-10 2008-02-11 Acme Drugs Srl Formulazioni intrasinoviali di stanozololo
US20090202645A1 (en) * 2008-02-08 2009-08-13 Acme Drugs S.R.L. Intrasynovial formulations of stanozolol
EP2894173B1 (en) * 2012-09-05 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Hyaluronic acid derivative having amino acid and steryl group introduced thereinto

Also Published As

Publication number Publication date
MX2020009680A (es) 2020-10-12
PL3768729T3 (pl) 2022-05-02
SI3768729T1 (sl) 2022-04-29
EP3768729B1 (en) 2022-01-26
RS63033B1 (sr) 2022-04-29
WO2019180548A1 (en) 2019-09-26
DK3768729T3 (da) 2022-02-07
JP2021518378A (ja) 2021-08-02
KR102709660B1 (ko) 2024-09-26
CA3094277A1 (en) 2019-09-26
PT3768729T (pt) 2022-03-11
IT201800003841A1 (it) 2019-09-21
IL277319B2 (en) 2024-02-01
KR20200135824A (ko) 2020-12-03
CN111868097A (zh) 2020-10-30
EP3768729A1 (en) 2021-01-27
HRP20220166T1 (hr) 2022-04-29
IL277319A (en) 2020-10-29
IL277319B1 (en) 2023-10-01
US20210038735A1 (en) 2021-02-11
CY1124939T1 (el) 2023-01-05
ES2908887T3 (es) 2022-05-04
CN111868097B (zh) 2023-06-06
AU2019240175A1 (en) 2020-11-12
HUE058230T2 (hu) 2022-07-28
AU2019240175B2 (en) 2024-05-02
US11013813B2 (en) 2021-05-25
JP7301392B2 (ja) 2023-07-03

Similar Documents

Publication Publication Date Title
SG11202105128RA (en) Conjugates and nanoparticles of hyaluronic acid and epigallocatechin-3-o-gallate and uses thereof
EP3706803A4 (en) CONJUGATES OF BIOMOLECULES AND THEIR USES
IL271692A (en) Tissue fillers based on hyaluronic acid and silk and methods of using them
EP3303634A4 (en) CASE VARIANTS9 AND METHODS OF USE THEREOF
IL274796A (en) Oxoacridinyl acetic acid derivatives and methods of use
IL275182A (en) Preparations and methods for the treatment of metabolic conditions
IL285928A (en) Fulvestrant formulations and methods of using them
IL279445A (en) Stabilized hyaluronic acid
EP3562446A4 (en) NOSE IMPLANTS AND METHOD OF USE
HK1256301A1 (zh) 提高阿托伐他汀和清除感染的新的 13 系列消退素的說明
IL291730A (en) Protein-macromolecule conjugates and methods for using them
IL283662A (en) Monomethyl fumarate conjugates - carrier and methods of using them
SG11202112129SA (en) Drug conjugates and methods of using same
EP3773654C0 (en) POLYPHARMACEUTICAL DRUG COMPOSITIONS AND ASSOCIATED METHODS
EP3409292A4 (en) AQUEOUS STABILIZED COMPOSITION COMPRISING CHONDROITIN SULFATE AND HYALURONIC ACID
EP3749691A4 (en) ANGPTL8 LIAISON AGENTS AND THEIR METHODS OF USE
IL274433A (en) Fulvestrant formulations and methods of using them
IL272511A (en) Assembling a connector and methods of use
EP3684309A4 (en) DEVICES AND METHODS FOR REDUCING CYSTINE CRYSTALS IN VIVO
EP3517537A4 (en) DEUTERED DERIVATIVE OF L-TETRAHYDROPALMATINE AND MEDICAL USE THEREOF
ZA202001174B (en) Pharmaceutical compositions containing hyaluronic acid and carnosine and relative use
EP3883618C0 (en) INJECTABLE COMPOSITION CONTAINING HYALURONIC ACID AND USE OF SAID COMPOSITION
IL262036A (en) Hyaluronic acid conjugates and uses thereof
PL3662761T3 (pl) Stabilne podczas przechowywania adsorbaty związków nitrooksy
EP3710069A4 (en) COMPOSITIONS OF FLUORESCEIN AND BENOXINATE